The tweet was deleted by the author.
But we saved everything 🙂.
C4 Therapeutics, Inc. announced its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference. The session is scheduled for June 4 at 9:20 am ET.
The appearance represents a key opportunity for the company to discuss strategic positioning and ongoing initiatives with investors and industry peers. Conference participation by management teams often signals engagement with stakeholders and provides insight into a company’s direction.
C4 Therapeutics has recently highlighted progress on its Phase 2 clinical trial for cemsidomide in multiple myeloma at ASCO26. The company is also scheduled to present new Phase 1 data on cemsidomide for refractory multiple myeloma at the EHA Hematology 2026 Congress. These presentations reflect C4 Therapeutics' continued activity in clinical research.